Company intelligence / Profile preview

SignalChem Lifesciences

Richmond, British Columbia, Canada

Ownership: Private
Development stage: Other

Overview

SignalChem Lifesciences is a clinical-stage oncology company with a portfolio of small-molecule inhibitors targeting novel kinase pathways. The lead program SLC-391 (AXL inhibitor) is in Phase 1b/2 development for non-small cell lung cancer in combination with pembrolizumab, with ongoing recruitment as of the search results.[2] The company also has SLC-0111 (CAIX inhibitor) in development for pancreatic cancer and other programs targeting RON and CSF1R.[2]

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

Leading pharmaceutical companies for compound profilingAcademic and research institutionsContract research organizations

Beyond the preview

Go deeper on SignalChem Lifesciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SignalChem Lifesciences.

Explore the full profile